Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mesenchymal stem cell-induced metabolic reprogramming of EGFR-wild-type tumor cells drives therapeutic resistance in EGFR-mutant non-small cell lung cancer.

Journal of experimental & clinical cancer research : CR - 11 Jul 2026

Bie Hongyu, Li Jiarui, Liu Jialin, Zhou Jian, Wang Tierun, Guo Xu, Liu Jiawei, You Yi, Huang Hui, Li Shijia, Li Wanqiao, Ren Xiubao, Wang Meng, Zhang Wencheng, Yan Cihui

Abstract excerpt

BACKGROUND: To explore mesenchymal stem cell (MSC)-driven metabolic reprogramming of EGFR-wild-type (EGFR-wt) tumor cells contributing to tyrosine kinase inhibitor (TKI) resistance in EGFR-mutant (EGFR-mt) non-small cell lung cancer. METHODS: Isolate MSCs from paired tumor and non-tumor lungs of EGFR-mt and EGFR-wt patients. Integrate transcriptional RNA sequencing, targeted free fatty acid and energy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mesenchymal Stem Cells

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 42436555
DOI: 10.1186/s13046-026-03748-w
PMCID: PMC13499310

Genes

EGFR
MSC
FASN
S100A9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mesenchymal stem cell-induced metabolic reprogramming of EGFR-wild-type tumor cells drives therapeutic resistance in EGFR-mutant non-small cell lung cancer.PMID 42436555Read ↗

Therapeutic strategies of metabolic reprogramming in non-small cell lung carcinoma.Semantic proximity Read ↗

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC.Semantic proximity Read ↗

Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.Semantic proximity Read ↗

The Role of Mesenchymal Stem Cells in Drug Resistance in Lung NeoplasmsSemantic proximity Read ↗

Role of metabolic reprogramming in drug resistance to epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Genomic alterations and their correlation with metabolic-related genes in lung cancer.Semantic proximity Read ↗

A novel mouse cell line model reveals the tumor intrinsic and immune characteristics of EGFR-mutant lung cancer.Semantic proximity Read ↗

Shining a light on metabolic vulnerabilities in non-small cell lung cancer.Semantic proximity Read ↗

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.Semantic proximity Read ↗

Lineage Plasticity and Histologic Transformation in EGFR-TKI Resistant Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.